Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.

Abstract

SQ 33,261 ([1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-6-[3-[[2- [(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2 - yl]-4-hexenoic acid) and SQ 33,552 ([1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-6-[3-[[[[(4- chlorophenyl)amino]carbonyl]hydrazono]methyl]-7- oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid) are potent thromboxane (Tx) A2 receptor antagonists. They inhibited platelet aggregation in platelet-rich plasma induced by the TxA2 mimetic, U-46,619 (10 microM), with IC50 values of 200 and 70 nM, respectively. Neither compound inhibited ADP (20 microM)-induced platelet aggregation (IC50 greater than 1000 microM). SQ 33,261 and SQ 33,552 competitively antagonized U-46,619-induced contraction of rat aortic strips with respective pA2 values of 9.0 and 10.1 and KB values of 1.2 and 0.1 nM. They also competitively antagonized U-46,619-induced contraction of guinea pig tracheal strips with pA2 values of 8.9 and 9.9 and KB values of 1.9 and 0.4 nM, respectively. SQ 33,261 and SQ 33,552 (p.o.) were potent inhibitors of U-46,619 (2 mg/kg i.v.)-induced death in mice with ID50 values of 8 and 1 micrograms/kg, respectively. SQ 33,261 and SQ 33,552 (0.2 mg/kg p.o.), also had long duration of action in this assay with 50% survival times of 7 and 15 hr, respectively. SQ 33,261 at 0.01 and 1.0 mg/kg i.v., inhibited arachidonic acid-induced bronchoconstriction and reversed arachidonic acid-induced hypertension to a hypotensive response. SQ 33,552 inhibited TxA2 synthase at high concentrations (IC50 = 307 microM), whereas SQ 33,261 was inactive. Neither compound inhibited cyclooxygenase or caused an elevation of platelet cyclic AMP levels.(ABSTRACT TRUNCATED AT 250 WORDS)

• Authors: D N Harris, I M Michel, H J Goldenberg, K S Hartl, G T Allen, T E Steinbacher, W A Schumacher, W C Han, S E Hall, D M Floyd
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 261 Issue 1 Pg. 131-7 (Apr 1992) ISSN: 0022-3565 [Print] United States
• PMID: 1532833 (Publication Type: Journal Article)

Chemical References

• Bridged Bicyclo Compounds
• Bridged Bicyclo Compounds, Heterocyclic
• Fatty Acids, Unsaturated
• Hydrazines
• Hydrazones
• Platelet Aggregation Inhibitors
• Prostaglandin Endoperoxides, Synthetic
• Receptors, Prostaglandin
• Receptors, Thromboxane
• Vasoconstrictor Agents
• SQ 33261
• SQ 33552
• Thromboxane A2
• 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
• SQ 29548
• Thromboxane-A Synthase

Topics

• 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
• Animals
• Blood Pressure (drug effects)
• Bridged Bicyclo Compounds (pharmacology)
• Bridged Bicyclo Compounds, Heterocyclic
• Fatty Acids, Unsaturated
• Guinea Pigs
• Humans
• Hydrazines (pharmacology)
• Hydrazones (pharmacology)
• Male
• Mice
• Muscle Contraction (drug effects)
• Muscle, Smooth (drug effects)
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (pharmacology)
• Prostaglandin Endoperoxides, Synthetic (toxicity)
• Radioimmunoassay
• Rats
• Receptors, Prostaglandin (antagonists & inhibitors)
• Receptors, Thromboxane
• Thromboxane A2 (antagonists & inhibitors)
• Thromboxane-A Synthase (metabolism)
• Vasoconstrictor Agents (toxicity)